NURS 6521 / NURS6521 Advanced Pharmacology
Midterm Exam Practice Actual 2025/2026 with Detailed
Rationales | 100% Verified | Pass Guaranteed – A+
Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (12 questions)
Q1: A patient with severe liver disease is prescribed a benzodiazepine for anxiety.
The nurse practitioner should select lorazepam over diazepam primarily because
lorazepam:
A. Is metabolized by glucuronidation rather than oxidation, making it safer in hepatic
impairment
B. Has a shorter half-life and therefore less accumulation
C. Is excreted unchanged by the kidneys and does not undergo hepatic metabolism
D. Is a prodrug that requires hepatic activation to become active
Correct Answer: A
Rationale: Lorazepam undergoes glucuronidation (Phase II metabolism), which is
relatively preserved in liver disease compared to oxidation (Phase I metabolism)
used by diazepam, making it the preferred benzodiazepine in patients with hepatic
impairment.
Q2: A patient taking phenytoin for seizures has subtherapeutic drug levels despite
adherence to the prescribed dose. The nurse practitioner discovers the patient
,consistently takes phenytoin with meals. Which pharmacokinetic principle explains
this finding?
A. Food increases hepatic blood flow, accelerating first-pass metabolism
B. Food decreases gastrointestinal absorption by increasing gastric pH
C. Food increases plasma protein binding, reducing free drug concentration
D. Food induces CYP450 enzymes, increasing phenytoin clearance
Correct Answer: B
Rationale: Phenytoin absorption is decreased by food and antacids that increase
gastric pH; the drug should be taken on an empty stomach or separated from meals
to ensure consistent absorption and therapeutic plasma levels.
Q3: A new antihypertensive drug has an ED50 of 5 mg and an LD50 of 50 mg. A
competing drug has an ED50 of 10 mg and an LD50 of 200 mg. Which statement
accurately compares these drugs?
A. The new drug is more potent but has a narrower therapeutic index
B. The competing drug is more potent and has a wider therapeutic index
C. The new drug is more efficacious and safer than the competing drug
D. The competing drug is less potent but equally efficacious
Correct Answer: A
Rationale: The new drug has a lower ED50 (5 mg vs. 10 mg), making it more potent,
but its therapeutic index is 10 (50/5) compared to 20 (200/10) for the competing
drug, indicating a narrower safety margin.
, Q4: A patient with renal failure receives a loading dose of vancomycin but no
maintenance doses. The nurse practitioner explains that the loading dose is based
on which pharmacokinetic parameter?
A. Volume of distribution, to achieve the target concentration immediately
B. Clearance, to maintain the steady-state concentration
C. Half-life, to determine the dosing interval
D. Bioavailability, to compensate for first-pass metabolism
Correct Answer: A
Rationale: The loading dose is calculated based on the volume of distribution and
the desired target plasma concentration to rapidly achieve therapeutic levels,
independent of clearance or half-life.
Q5: A patient is prescribed propranolol and soon develops wheezing and
bronchospasm. The nurse practitioner recognizes this as an adverse effect related to
which pharmacodynamic property?
A. Non-selective beta-adrenergic blockade affecting beta-2 receptors in the lungs
B. Selective beta-1 blockade causing unopposed alpha-adrenergic stimulation
C. Intrinsic sympathomimetic activity stimulating beta-2 receptors
D. Membrane-stabilizing activity causing direct bronchial smooth muscle contraction
Correct Answer: A
Rationale: Propranolol is a non-selective beta-blocker that blocks beta-2 receptors in
bronchial smooth muscle, preventing bronchodilation and potentially causing
bronchospasm in patients with asthma or COPD.
Midterm Exam Practice Actual 2025/2026 with Detailed
Rationales | 100% Verified | Pass Guaranteed – A+
Graded
SECTION 1: Pharmacokinetics & Pharmacodynamics (12 questions)
Q1: A patient with severe liver disease is prescribed a benzodiazepine for anxiety.
The nurse practitioner should select lorazepam over diazepam primarily because
lorazepam:
A. Is metabolized by glucuronidation rather than oxidation, making it safer in hepatic
impairment
B. Has a shorter half-life and therefore less accumulation
C. Is excreted unchanged by the kidneys and does not undergo hepatic metabolism
D. Is a prodrug that requires hepatic activation to become active
Correct Answer: A
Rationale: Lorazepam undergoes glucuronidation (Phase II metabolism), which is
relatively preserved in liver disease compared to oxidation (Phase I metabolism)
used by diazepam, making it the preferred benzodiazepine in patients with hepatic
impairment.
Q2: A patient taking phenytoin for seizures has subtherapeutic drug levels despite
adherence to the prescribed dose. The nurse practitioner discovers the patient
,consistently takes phenytoin with meals. Which pharmacokinetic principle explains
this finding?
A. Food increases hepatic blood flow, accelerating first-pass metabolism
B. Food decreases gastrointestinal absorption by increasing gastric pH
C. Food increases plasma protein binding, reducing free drug concentration
D. Food induces CYP450 enzymes, increasing phenytoin clearance
Correct Answer: B
Rationale: Phenytoin absorption is decreased by food and antacids that increase
gastric pH; the drug should be taken on an empty stomach or separated from meals
to ensure consistent absorption and therapeutic plasma levels.
Q3: A new antihypertensive drug has an ED50 of 5 mg and an LD50 of 50 mg. A
competing drug has an ED50 of 10 mg and an LD50 of 200 mg. Which statement
accurately compares these drugs?
A. The new drug is more potent but has a narrower therapeutic index
B. The competing drug is more potent and has a wider therapeutic index
C. The new drug is more efficacious and safer than the competing drug
D. The competing drug is less potent but equally efficacious
Correct Answer: A
Rationale: The new drug has a lower ED50 (5 mg vs. 10 mg), making it more potent,
but its therapeutic index is 10 (50/5) compared to 20 (200/10) for the competing
drug, indicating a narrower safety margin.
, Q4: A patient with renal failure receives a loading dose of vancomycin but no
maintenance doses. The nurse practitioner explains that the loading dose is based
on which pharmacokinetic parameter?
A. Volume of distribution, to achieve the target concentration immediately
B. Clearance, to maintain the steady-state concentration
C. Half-life, to determine the dosing interval
D. Bioavailability, to compensate for first-pass metabolism
Correct Answer: A
Rationale: The loading dose is calculated based on the volume of distribution and
the desired target plasma concentration to rapidly achieve therapeutic levels,
independent of clearance or half-life.
Q5: A patient is prescribed propranolol and soon develops wheezing and
bronchospasm. The nurse practitioner recognizes this as an adverse effect related to
which pharmacodynamic property?
A. Non-selective beta-adrenergic blockade affecting beta-2 receptors in the lungs
B. Selective beta-1 blockade causing unopposed alpha-adrenergic stimulation
C. Intrinsic sympathomimetic activity stimulating beta-2 receptors
D. Membrane-stabilizing activity causing direct bronchial smooth muscle contraction
Correct Answer: A
Rationale: Propranolol is a non-selective beta-blocker that blocks beta-2 receptors in
bronchial smooth muscle, preventing bronchodilation and potentially causing
bronchospasm in patients with asthma or COPD.
